Program
Valsartan
Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.
Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.
Drug pageValsartan: every studyMany companies study it; this page follows only the 125 they lead. All 254 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 1060 open or running | phase 4since Sep 10, 2005 | Nov 30, 2004 | none ahead |
| LG Chemits history only | 50 open or running | phase 3since Aug 5, 2013 | May 11, 2010 | none ahead |
| IlDong Pharmaceuticalits history only | 20 open or running | phase 3since May 20, 2014 | May 20, 2014 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Jul 21, 2014 | Jul 21, 2014 | none ahead |
| ARKAY Therapeuticsits history only | 10 open or running | phase 2since Sep 23, 2018 | Sep 23, 2018 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Aug 3, 2015 | Aug 3, 2015 | none ahead |
| EMSits history only | 10 open or running | phase 3since Nov 23, 2015 | Nov 23, 2015 | none ahead |
| Farma de Colombiaits history only | 10 open or running | phase 3since May 7, 2013 | May 7, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 1since Aug 2, 2018 | Aug 2, 2018 | none ahead |
| JW Pharmaceuticalits history only | 10 open or running | phase 1since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Mar 4, 2025 | Mar 4, 2025 | Dec 2027phase 3 · NCT06863987 |
| TSH Biopharmits history only | 10 open or running | phase 4since Feb 4, 2014 | Feb 4, 2014 | none ahead |
| Yuhanits history only | 10 open or running | phase 1since Jan 5, 2012 | Jan 5, 2012 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 22, 2007.
- Jan 15, 2015Phase 1 study in HypertensionIlDong Pharmaceutical · NCT02343250 · 54 enrolled
- Jul 30, 2015Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02519010 · 36 enrolled · Egypt
- Aug 3, 2015Dexa Medica Group’s first study: no phase study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT02518451 · 48 enrolled · Indonesia
- Nov 23, 2015EMS’ first study: phase 3 study in HypertensionNew to EMSEMS · NCT02662894
- Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNovartis · NCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
- May 8, 2018Phase 1 study in Healthy Male VolunteersLG Chem · NCT03532854 · 42 enrolled · Korea, Republic of
- Aug 2, 2018Hanlim Pharm.’s first study: phase 1 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT03648333 · 27 enrolled
- Sep 23, 2018ARKAY Therapeutics’ first study: phase 2 study in Diabetes Mellitus, Type 2New to ARKAY TherapeuticsARKAY Therapeutics · NCT03686657 · United States
- Dec 20, 2018Phase 3 study in Heart FailureNovartis · NCT03785405 · 216 enrolled · United States, Argentina, Austria and more
- Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)Novartis · NCT03988634 · 467 enrolled · United States, Canada
- Jul 10, 2019Phase 4 study in Chagas DiseaseNovartis · NCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
- Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNovartis · NCT04637555
- Nov 13, 2023Phase 3 study in Heart FailureNovartis · NCT06149104 · 8 enrolled · Japan
- Mar 4, 2025Lunan Pharmaceutical Group’s first study: phase 3 study in Essential HypertensionNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06863987 · 342 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in Essential HypertensionLunan Pharmaceutical Group · NCT06863987
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The newest 60 of 125 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06863987Essential Hypertension · China | 3 | By invitation | Lunan Pharmaceutical Group | Dec 2027 | 342 |
| NCT06149104Heart Failure · Japan | 3 | Completed | Novartis | Aug 14, 2024 | 8 |
| NCT04637555Post Myocardial Infarction | 3 | Withdrawn | Novartis | Jun 1, 2023 | 0 |
| NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more | 4 | Completed | Novartis | Mar 16, 2025 | 922 |
| NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada | 3 | Completed | Novartis | Dec 14, 2022 | 467 |
| NCT03785405Heart Failure · United States, Argentina, Austria and more | 3 | Completed | Novartis | Dec 29, 2023 | 216 |
| NCT03686657Diabetes Mellitus, Type 2 · United States | 2 | Withdrawn | ARKAY Therapeutics | Dec 26, 2030 | 0 |
| NCT03648333Hypertension | 1 | Completed | Hanlim Pharm. | Feb 2014 | 27 |
| NCT03532854Healthy Male Volunteers · Korea, Republic of | 1 | Completed | LG Chem | Aug 25, 2018 | 42 |
| NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more | 3 | Completed | Novartis | Oct 28, 2019 | 2,572 |
| NCT02662894Hypertension | 3 | Withdrawn | EMS | Sep 2020 | 0 |
| NCT02518451Healthy · Indonesia | – | Completed | Dexa Medica Group | Oct 2013 | 48 |
| NCT02519010Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2011 | 36 |
| NCT02343250Hypertension | 1 | Completed | IlDong Pharmaceutical | Mar 2015 | 54 |
| NCT02197494Healthy · India | – | Completed | Sun Pharmaceutical Industries | Feb 2014 | 40 |
| NCT02197442Healthy · India | – | Completed | Sun Pharmaceutical Industries | Feb 2014 | 36 |
| NCT02145104Hypertension · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 7, 2016 | 286 |
| NCT02062645Essential Hypertension · Turkey | 4 | Completed | Novartis | Sep 2015 | 115 |
| NCT02058446Essential Hypertension · Taiwan | 4 | Completed | TSH Biopharm | Mar 2014 | 36 |
| NCT01928628Hypertension · Korea, Republic of | 3 | Completed | LG Chem | Apr 2013 | 449 |
| NCT01918358Hypertension · Korea, Republic of | 1 | Completed | LG Chem | Jan 2013 | 60 |
| NCT01918332Hypertension · Korea, Republic of | 3 | Completed | LG Chem | Mar 2013 | 168 |
| NCT01850160Hypertension · Colombia, Ecuador | 3 | Completed | Farma de Colombia | Mar 2015 | 124 |
| NCT01617681Hypertension · Belgium, Brazil, France and more | 3 | Completed | Novartis | Jan 24, 2017 | 127 |
| NCT01541189Hypertension · China | 4 | Completed | Novartis | Jan 2013 | 200 |
| NCT01609907Hypertension · Korea, Republic of | 1 | Completed | Yuhan | May 2012 | 30 |
| NCT01447485Hypertension · Japan | 1 | Completed | Novartis | Oct 2011 | 12 |
| NCT01406431Hyperlipidemias · Korea, Republic of | 1 | Completed | JW Pharmaceutical | Aug 2011 | 48 |
| NCT01365481Hypertension · Colombia, Finland, Germany and more | 3 | Completed | Novartis | Sep 2015 | 150 |
| NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more | 2 | Completed | Novartis | Dec 2011 | 910 |
| NCT01241487Essential Hypertension · Egypt | 4 | Completed | Novartis | Jan 2011 | 150 |
| NCT01167153Hypertension · China | 4 | Completed | Novartis | Apr 2011 | 564 |
| NCT01122251Essential Hypertension · Korea, Republic of | 2 | Completed | LG Chem | May 2010 | 441 |
| NCT01001572Essential Hypertension | 3 | Completed | Novartis | May 2010 | 932 |
| NCT00939588Hypertension · Russian Federation | 2 | Completed | Novartis | Dec 2009 | 88 |
| NCT00931710Isolated Systolic Hypertension · United States | 4 | Completed | Novartis | Jan 2010 | 488 |
| NCT00902304Hypertension · United States, Australia | 4 | Completed | Novartis | Jul 2011 | 2,337 |
| NCT00821574Hypertension | 4 | Completed | Novartis | Mar 2007 | 144 |
| NCT00809926Hypertension · United States | 4 | Completed | Novartis | Jul 2009 | 451 |
| NCT00698646Hypertension · United States | 4 | Completed | Novartis | Jun 2009 | 384 |
| NCT00699192Hypertension · Czech Republic, Finland, France and more | 3 | Completed | Novartis | May 2009 | 965 |
| NCT00666536Hypertension · United States | 4 | Completed | Novartis | Jan 2009 | 728 |
| NCT00687973Hypertension · France | 4 | Completed | Novartis | Jan 2009 | 393 |
| NCT00700271Hypertension · France, Tunisia | 4 | Completed | Novartis | Aug 2008 | 478 |
| NCT00550095Proteinuria · Egypt | 4 | Completed | Novartis | Nov 2009 | 509 |
| NCT00548067Hypertension · India | 3 | Completed | Novartis | 111 | |
| NCT00523744Hypertension · Germany | 3 | Completed | Novartis | Dec 2007 | 257 |
| NCT00523549Hypertension · United States | 4 | Completed | Novartis | Jan 2008 | 229 |
| NCT00487123Hypertension · Singapore | 4 | Completed | Novartis | Sep 2007 | |
| NCT00457626Hypertension · United States, Belgium, Brazil and more | 3 | Completed | Novartis | May 25, 2009 | 66 |
| NCT00446563Hypertension · Germany | 3 | Completed | Novartis | Mar 2010 | 90 |
| NCT00446524Hypertension · Japan | 3 | Completed | Novartis | Oct 2008 | 403 |
| NCT00446511Hypertension · United States, Belgium, France and more | 3 | Completed | Novartis | Jun 2009 | 250 |
| NCT00439738Hypertension · United States | 4 | Completed | Novartis | Nov 2007 | 412 |
| NCT00437645Essential Hypertension · Argentina, Chile, Ecuador and more | 3 | Completed | Novartis | Nov 2007 | 1,183 |
| NCT00435162Hypertension · United States, Belgium, Brazil and more | 3 | Completed | Novartis | Jan 2009 | 74 |
| NCT00433836Hypertension · United States, Belgium, France and more | 3 | Completed | Novartis | Feb 2009 | 300 |
| NCT00426478Hypertension · Taiwan | 4 | Completed | Novartis | 80 | |
| NCT00425997Hypertension · United States | 4 | Completed | Novartis | Oct 2007 | 480 |
| NCT00425373Essential Hypertension · Japan | 3 | Completed | Novartis | Mar 2008 | 1,474 |
How it is read
Names in the registry
- “Valsartan”, 31 entries
- “valsartan”, 23 entries
- “sacubitril/valsartan”, 5 entries
- “valsartan plus hydrochlorothiazide”, 5 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 98 studies
- Essential Hypertension, 10 studies
- Heart Failure, 8 studies
- Diabetes Mellitus, Type 2, 5 studies
- Proteinuria, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.